LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026
LENSAR (Nasdaq: LNSR) will release its third-quarter 2026 financial results before market open on Tuesday, November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LENSAR (Nasdaq: LNSR) will release its third-quarter 2026 financial results before market open on Tuesday, November 10, 2026. Management will host a conference call and webcast at 8:30 am ET that day to discuss the results and recent operational highlights. An archived version will be available on the company’s website after the live webcast.
Details
News Market Reaction – LNSR
On Nov 3, the day this news came out, LNSR closed 1.76% below the previous close. Argus tracked a peak move of +2.2% during that session. Our momentum scanner recorded 7 alerts in the available session data. That session’s volume was 2.5x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 3 session.
Key Figures
- Results release date
- November 10, 2026
- Third quarter 2026 financial results; before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2026 financial results will be released before market open on Tuesday, November 10, 2026. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Tuesday, November 10, 2026 to discuss the results and recent operational highlights.
To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth | |
| Mike Rossi, Interim CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com |
